Furthermore, the response seen with tamoxifen monotherapy in a patient with prolactin-secreting cancer suggests that tamoxifen might have a direct effect on prolactin secretion that is independent of DA action, yet the magnitude of this effect remains to be elucidated. This evidence concerns the gene PRL and cancer.